European Union Looks To Buy 1.8B Pfizer-BioNTech COVID-19 Vaccine Doses From 2022: Reuters
European Union Looks To Buy 1.8B Pfizer-BioNTech COVID-19 Vaccine Doses From 2022: Reuters
歐盟希望從2022年開始購買18億劑輝瑞-生物科技新冠肺炎疫苗：路透社
- The European Commission is reportedly seeking EU governments’ approval to get into talks with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to purchase up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, Reuters reported.
- Earlier today, German daily Die Welt reported that the Commission was to sign contracts shortly to buy up to 1.8 billion doses but did not say with which company.
- A Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.
- “If provided the opportunity, Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.
- Both the companies have already said that they can produce more than 3 billion doses of vaccine in 2022.
- According to another Reuters report, Australia has doubled its order of the PFE COVID-19 vaccine, Prime Minister Scott Morrison said, as the country raced to rebuild its vaccination program after concerns about blood clot risks from AstraZeneca Plc (NASDAQ: AZN) vaccine.
- Australia based its vaccination program primarily on an AstraZeneca shot until late Thursday, with an order for 50 million doses.
- But Australia has now joined a host of countries in restricting the use of the AZN vaccine. The Australian authorities now recommend that the country’s nearly 12 million people aged under 50 should take the Pfizer product instead.
- As a result, Australia has doubled an earlier Pfizer order to 40 million shots, which would be delivered by the end of the year.
- The policy change to use the Pfizer vaccine effectively ends plans to have the entire population vaccinated by the end of October.
- Price Action: JNJ shares are down 1.8% at $159.95, while Pfizer shares are up 1.10% at $36.36 during market trading hours on the last check Friday.
- The European Commission is reportedly seeking EU governments’ approval to get into talks with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to purchase up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, Reuters reported.
- Earlier today, German daily Die Welt reported that the Commission was to sign contracts shortly to buy up to 1.8 billion doses but did not say with which company.
- A Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.
- “If provided the opportunity, Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.
- Both the companies have already said that they can produce more than 3 billion doses of vaccine in 2022.
- According to another Reuters report, Australia has doubled its order of the PFE COVID-19 vaccine, Prime Minister Scott Morrison said, as the country raced to rebuild its vaccination program after concerns about blood clot risks from AstraZeneca Plc (NASDAQ: AZN) vaccine.
- Australia based its vaccination program primarily on an AstraZeneca shot until late Thursday, with an order for 50 million doses.
- But Australia has now joined a host of countries in restricting the use of the AZN vaccine. The Australian authorities now recommend that the country’s nearly 12 million people aged under 50 should take the Pfizer product instead.
- As a result, Australia has doubled an earlier Pfizer order to 40 million shots, which would be delivered by the end of the year.
- The policy change to use the Pfizer vaccine effectively ends plans to have the entire population vaccinated by the end of October.
- Price Action: JNJ shares are down 1.8% at $159.95, while Pfizer shares are up 1.10% at $36.36 during market trading hours on the last check Friday.
- 據報道，歐盟委員會正在尋求歐盟各國政府的批准，以便與歐盟展開談判輝瑞公司(紐約證券交易所股票代碼：PFE)和BioNTech SE據路透社報道，納斯達克股票代碼：BNTX)將購買多達18億劑新冠肺炎疫苗，將於2022年和2023年交付。
- 今天早些時候，德國日報Die Welt報道稱，歐盟委員會不久將簽署合同，購買多達18億劑疫苗，但沒有透露與哪家公司。
- 歐盟委員會的一位發言人證實了購買額外劑量的計劃，其中一半將是可選的。
- 輝瑞的一位發言人説：“如果有機會，輝瑞和BioNTech準備在2022年和2023年向歐洲供應數億劑由我們在歐洲的製造設施生產的COVID疫苗。”
- 兩家公司已經表示，他們在2022年可以生產超過30億劑疫苗。
- 根據路透社的另一篇報道，澳大利亞總理斯科特·莫里森表示，澳大利亞已經將PFE新冠肺炎疫苗的訂單增加了一倍，因為在擔心血液凝塊風險之後，澳大利亞正在競相重建其疫苗接種計劃。阿斯利康(AstraZeneca Plc)(納斯達克市場代碼：AZN)疫苗。
- 澳大利亞的疫苗接種計劃主要是基於阿斯利康(AstraZeneca)的疫苗注射，直到週四晚些時候，已經訂購了5000萬劑。
- 但澳大利亞現在加入了許多國家的行列，限制AZN疫苗的使用。澳大利亞當局現在建議該國近1200萬年齡在50歲以下的人轉而服用輝瑞產品。
- 因此，澳大利亞將輝瑞早些時候的訂單翻了一番，達到4000萬針，將在今年年底前交付。
- 使用輝瑞疫苗的政策變化實際上結束了在10月底之前讓所有人接種疫苗的計劃。
- 價格行動：摩根大通股價下跌1.8%，至159.95美元，輝瑞股價在週五最後一次交易時段上漲1.10%，至36.36美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！